# Louisville Metabolic and Atherosclerosis Research Center

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/louisville-metabolic-and-atherosclerosis-research-center/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 87 |
| Citations | 102,554 |
| City | Louisville |
| Country | US |
| Description | Louisville Metabolic and Atherosclerosis Research Center is a research organisation in Louisville, US. OpenAlex records 743 works and 102,554 citations for it. 73 researchers list it as their most recent affiliation. |
| Homepage | http://www.lmarc.com/ |
| OpenAlex ID | https://openalex.org/I4210132010 |
| Region | Kentucky |
| Researchers | 73 |
| ROR ID | https://ror.org/030y83r80 |
| Type | facility |
| Works | 743 |

## University papers

- [Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients](https://scholariq.org/papers/bempedoic-acid-and-cardiovascular-outcomes-in-statin-intolerant-patients/)
- [National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2](https://scholariq.org/papers/national-lipid-association-recommendations-for-patient-centered-management-of/)
- [National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report](https://scholariq.org/papers/national-lipid-association-recommendations-for-patient-centered-management-of-3/)
- [PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes](https://scholariq.org/papers/pioneer-1-randomized-clinical-trial-of-the-efficacy-and-safety-of-oral/)
- [National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary](https://scholariq.org/papers/national-lipid-association-recommendations-for-patient-centered-management-of-2/)
- [Efficacy and tolerability of adding prescription Omega-3 fatty acids 4 g/d to Simvastatin 40 mg/d in hypertriglyceridemic patients: An 8-week, randomized, double-blind, placebo-controlled study](https://scholariq.org/papers/efficacy-and-tolerability-of-adding-prescription-omega-3-fatty-acids-4-g-d-to/)
- [Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial](https://scholariq.org/papers/efficacy-and-safety-of-oral-semaglutide-with-flexible-dose-adjustment-versus/)

## University top topics

Showing 8 of 25.

- [Lipoproteins and Cardiovascular Health](https://scholariq.org/topics/lipoproteins-and-cardiovascular-health/)
- [Diabetes, Cardiovascular Risks, and Lipoproteins](https://scholariq.org/topics/diabetes-cardiovascular-risks-and-lipoproteins/)
- [Cancer, Lipids, and Metabolism](https://scholariq.org/topics/cancer-lipids-and-metabolism/)
- [Pharmacology and Obesity Treatment](https://scholariq.org/topics/pharmacology-and-obesity-treatment/)
- [Fatty Acid Research and Health](https://scholariq.org/topics/fatty-acid-research-and-health/)
- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Lipid metabolism and disorders](https://scholariq.org/topics/lipid-metabolism-and-disorders/)
- [Cholesterol and Lipid Metabolism](https://scholariq.org/topics/cholesterol-and-lipid-metabolism/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.